{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n In a recent study on glioblastoma (GBM), FRY‐AS1 was identified as one of five long non‐coding RNAs whose differential expression was significantly associated with patient survival, leading to the development of a robust multi‐lncRNA risk score model for predicting therapeutic efficacy and prognosis (1). Analysis of lncRNA sequencing data from TCGA and CGGA GBM samples revealed that elevated expression levels of FRY‐AS1 contributed, along with the other signature lncRNAs, to a high‐risk score that correlated with poor overall survival. Moreover, gene set enrichment analysis indicated that patients with higher risk scores, reflecting increased FRY‐AS1 expression among other factors, exhibited enrichment in crucial signaling pathways, including PI3K-Akt, VEGFA-VEGFR2, TGF-beta, Notch, and T-cell pathways, which are known to drive oncogenic progression in GBM. These findings suggest that FRY‐AS1 may play an important role as a prognostic biomarker and could potentially guide therapeutic strategies in GBM (1)."}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Xuegang Niu, Jiangnan Sun, Lingyin Meng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A Five-lncRNAs Signature-Derived Risk Score Based on TCGA and CGGA for Glioblastoma: Potential Prospects for Treatment Evaluation and Prognostic Prediction."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Front Oncol (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3389/fonc.2020.590352"}], "href": "https://doi.org/10.3389/fonc.2020.590352"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33392085"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33392085"}]}]}]}